Cargando…
NQPC-05 BEVACIZUMAB AFTER PROGRESSION OF GLIOBLASTOMA PROLONGS PATIENT’S LIVING TIME AT HOME IN THE LAST 90 DAYS
Bevacizumab (Bev) is currently available for recurrent glioblastoma to improve a patient’s quality of life (QoL). To maintain a patient’s daily life activity, Bev is sometimes continued beyond radiographical progression until neurological deteriorations. However, the benefit of continuous use of Bev...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213194/ http://dx.doi.org/10.1093/noajnl/vdz039.136 |